banner_01 banner_02 banner_03 banner_04
    Home     Profile     Publications     Memberships     Lectures     Image Gallery     Contact Us
 
 
 
 
Latest News
Posted on 04.02.2012
Professor Gill\' team will be presenting their research work in European Association of study of liver diseases, being held in Barcelona in April 2012.

Posted on 10.12.2011
Professor Gill is invited by World Congress of Gastroenterology to give state of the art lecture \\\"Treatment challenges of chronic Hepatitis C. Conference is being held in Omaha USA from March 12 -14 2012.

Posted on 18.10.2011
Professor Gill is invited as a speaker in Ravello-Amalfi , Italy to give a talk on psychological implications of Hepatitis C diagnosis. in December 2012.

Posted on 28.07.2011
Professor Gill's team will be presenting 4 research papers in annual conference of ASIA PACIFIC DIGESTIVE DISEASE WEEK being held in Singapore in October 2011.

Posted on 27.01.2011
Professor Gill'S team will be presenting research work at EASL (european association of study of liver diseases) annual conference being held in Berlin Germany in April 2011

Posted on 03.12.2010
Professor Gill's team will be presenting 4 research papers in "The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011) 17-20 February 2011, QSNCC, Bangkok Thailand"

Posted on 22.07.2010
Consensus interferon treatment for Pegylated interferon relapsers Hepatitis C patients rated the best study by Pakistan Society of Gastroenterology Annual conference in Bhurbun Muree May 30th 2010.

Posted on 21.07.2010
Professor Gill's team work will be presented in Barcelona , Spain in UEGW (United european gastroenterology week) October 23 to October 27th 2010

Posted on 17.07.2010
Professor Gill's team work will be presented in Barcelona , Spain in UEGW (United european gastroenterology week) October 23 to October 27th 2010

Posted on 19.05.2010
World Hepatitis Day

Posted on 08.04.2010
New directions in hepatitis c treatment.

Posted on 08.04.2010
Treatment of hepatitis c revolutionized.

Posted on 23.02.2010
Dr. Gill is invited to the 20th Conference of the APASL, to be held at the China National Convention Center, 25 to 28 March 2010, Beijing, China.

Posted on 23.02.2010
Dr. Gill is invited to the International Liver CongressTM 2010 by EASL, taking place in Vienna, Austria, April 14 to 18, 2010.

Posted on 17.02.2010
New treatment for hep c non responders and relapsers

Posted on 08.01.2010
Treatment Challenges Of Hepatitis C Non Responders And Relapsers

Posted on 21.08.2009
Invited lecture on Hepatitis B and C co-infection management on 8th annual international conference of Gastroenterology and Hepatology in Faisalabad 25-26th july 2009

Posted on 22.06.2009
State of the art lecture on management of chronic hepatitis B, PSSLD single topic conference in Rawalpindi.

 
New directions in hepatitis c treatment.
08.04.2010
Short Description :
New directions in hepatitis c treatment.
Long Description::

Chronic Hepatitis C treatment is a  rapidly changing arena. There are rapidly changing guidelines about the type of interferon use and duration of treatment. We are able to understand the disease process better after 20 years of research to improve the diagnostic tools and treatment type and duration.

There are new tools and parameters, both patient and doctors who are caring for these patients, need to understand. In 2010 viral kinetics is very important .It has to do with how the hepatitis C virus/human body response to introduction of Pegylated interferon .How quickly patient becomes HCVPCR negative. This is reflective of hepatitis C free i.e. no living virus in the body. If patient becomes HCVPCR negative after four Pegylated interferon injections, the chances are very high that particular individual will remain free of disease after completion of the treatment.

We did conducted a study in Pakistani patients with hepatitis C genotype3  treated with Pegylated interferon and Ribavirin who were HCV PCR negative after 4 weeks of treatment and its impact after the completion of treatment.  90% patients stayed free of virus after 1 year completion of treatment. This is very important development and provides a roadmap for treatment policy, patients who are not HCV PCR negative after 4 injections they need more than 6 months of treatment. The patients who become HCVPCR negative after 12 injections will need at least 9 to 12 months of therapy. This treatment plan will decrease the chances of recurrence of disease. In Pakistan we are facing a challenge of poor choice of injection and rather inappropriate duration of treatment.

This work will be presented in 45h (EASL) European association of study of liver diseases meeting being held in  Vienna Austria from April 14th to April 18th...This study was conducted by young researchers Dr Uzma Adeeb and Dr Fatima Khattak, under the supervision of Professor Muzzaffar Gill  at Maroof International Hospital and Islamabad Specialists Clinic.